Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...
The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...